Omnicell, Inc. income statement

In fiscal 2025, Omnicell, Inc. reported revenue of $1.18bn, up 6.5% on the year before, operating income of $5.2m (a 0.4% margin) and net income of $2.1m, or $0.04 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Omnicell, Inc.: income statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	213	222	246	314	381	441	485	696	713	787	897	892	1,132	1,296	1,147	1,112	1,185	1,247
Cost of revenue	108	104	110	143	177	207	237	379	394	415	460	479	577	707	650	641	681	689
Gross profit	105	118	136	171	203	234	248	317	319	372	437	413	555	589	497	471	503	558
Research and development	18	21	22	24	29	28	35	58	66	65	69	70	76	105	97	90	89	88
Selling, general and administrative	86	86	98	120	139	156	168	238	241	263	290	308	389	486	435	380	410	412
Operating income	1	10	16	27	35	50	49	21	11	44	78	36	90	−2	−35	0	5	58
Interest expense	0	0	0	—	—	—	0	5	6	8	4	—	—	—	—	—	—	—
Provision for credit losses	—	—	—	0	0	—	—	—	—	—	—	—	—	—	—	—	—	—
Income before tax	1	10	16	27	35	49	46	13	5	36	74	29	66	−2	−20	26	11	61
Income tax	1	5	6	11	11	18	15	3	−26	−2	13	−3	−12	−8	0	13	9	22
Net income	0	5	10	16	24	31	31	10	31	38	61	32	78	6	−20	13	2	39
Diluted EPS	$0.01	$0.15	$0.30	$0.47	$0.67	$0.83	$0.84	$0.26	$0.79	$0.93	$1.43	$0.74	$1.62	$0.12	−$0.45	$0.27	$0.04	$0.85
Diluted shares (average)	32m	34m	34m	34m	36m	37m	37m	37m	39m	41m	43m	44m	48m	46m	45m	46m	46m	46m
EBITDA	10	18	24	40	54	70	74	80	63	96	132	97	162	85	52	83	84	135

US$ millions unless shown otherwise. Fiscal quarters.

Omnicell, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	282	307	270	291	311	314	310	312
Cost of revenue	160	165	159	163	176	184	170	159
Gross profit	122	142	111	128	135	130	140	153
Research and development	21	26	21	22	24	23	22	20
Selling, general and administrative	94	103	102	98	102	107	102	100
Operating income	7	12	−12	8	8	0	17	32
Income before tax	12	24	−10	10	10	1	17	34
Income tax	3	8	−3	5	4	3	6	10
Net income	9	16	−7	6	5	−2	11	24
Diluted EPS	$0.19	$0.34	−$0.15	$0.12	$0.12	−$0.05	$0.25	$0.52
EBITDA	27	32	8	28	28	20	35	51

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: OMCL vs WAY OMCL vs TEM GDRX vs OMCL

More: Health Care Technology stocks compared, Health Care sector, rankings of US companies

Figures from Omnicell, Inc.'s SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Omnicell, Inc.